ZYPADHERA 405 mg, powder and solvent for injectable suspension with extended release bottle, 3 ml
Active ingredients: Olanzapine, OLANZAPINE (PAMOATE D') MONOHYDRATÉ
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only, hospital use
Powder and solvent for injectable suspension with extended releasebottle, 3 mlintramusculaire
Supply resumed
Package details
Original BDPM fields are shown in French.
- Official name
- ZYPADHERA 405 mg, poudre et solvant pour suspension injectable à libération prolongée
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon(s) en verre - 1 flacon(s) en verre de 3 ml avec seringue(s) avec aiguille(s)
- Marketing authorisation holder
- CHEPLAPHARM REGISTRATION (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 26 Jan 2010
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65023242CIP75746939CIP133400957469399Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| OLANZAPINEpoudre | 405 mg · un flacon | FT |
| OLANZAPINE (PAMOATE D') MONOHYDRATÉpoudre | 931 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.